Reimbursement In Brief

MedCAC pharmacogenomics meeting: The Medicare Evidence Development and Coverage Advisory Committee will meet Jan. 27, 2010, in Baltimore to review evidence on the impact of pharmacogenomic testing on health outcomes in cancer patients. Specifically, the panel will assess assays that might be used as a guide for certain drug treatments for breast cancer, colon cancer, chronic myelogenous leukemia or metastatic colorectal cancer. The upcoming meeting is the third in a series of MedCAC discussions held this year on evidence supporting genetic and genomic screening (1"The Gray Sheet" May 25, 2009)